Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

[cafead]

via Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study.

article source